Even with ACL coming off heavy for its trial results its valuation is multiples of that of VHL , how VHL can only have a enterprise valuation of a few million is beyond me. Fair value purely on risk/reward compared to other Bio's would value this stock at least 2 to 3 cents per share imo.
